Analyses of the Local Control of Pulmonary Oligometastases after Stereotactic Body Radiotherapy and the Impact of Local Control on Survival

Autor: Atsuro Terahara, Yuzuru Niibe, Kazunari Yamada, Keiichi Jingu, Yoshihiko Manabe, Hideomi Yamashita, Katsuya Yahara, Takaya Yamamoto, Ryoong Jin Oh, Kuniaki Katsui, Takashi Shintani, Masatoki Ozaki, Mitsuru Kobayashi, Masahiko Aoki, Hiroshi Onishi, Atsushi Nishikawa
Rok vydání: 2020
Předmět:
0301 basic medicine
Adult
Male
Cancer Research
medicine.medical_specialty
Multivariate analysis
Lung Neoplasms
Adolescent
Stereotactic body radiotherapy
Metastasis-directed therapy
Radiosurgery
lcsh:RC254-282
Gastroenterology
Effective dose (radiation)
03 medical and health sciences
Young Adult
0302 clinical medicine
Surgical oncology
Internal medicine
Pulmonary oligometastases
Genetics
medicine
Humans
Sync-oligometastases
Survival analysis
Aged
Aged
80 and over

Performance status
business.industry
Proportional hazards model
Oligo-recurrence
Retrospective cohort study
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Survival Analysis
030104 developmental biology
Oncology
Local control
030220 oncology & carcinogenesis
Adenocarcinoma
Female
business
Research Article
Zdroj: BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
DOI: 10.21203/rs.3.rs-35650/v4
Popis: Background Successful local therapy for oligometastases may lead to longer survival. The purpose of this multicentre retrospective study was to investigate factors affecting the local control (LC) of pulmonary oligometastases treated by stereotactic body radiotherapy (SBRT) and to investigate the impact of LC on survival. Methods The inclusion criteria included 1 to 5 metastases, the primary lesion and other extrathoracic metastases were controlled before SBRT, and the biological effective dose (BED10) of the SBRT was 75 Gy or more. The Cox proportional hazards model was used for analyses. Results Data of 1378 patients with 1547 tumours from 68 institutions were analysed. The median follow-up period was 24.2 months. The one-year, 3-year and 5-year LC rates were 92.1, 81.3 and 78.6%, respectively, and the 1-year, 3-year and 5-year overall survival rates were 90.1, 60.3 and 45.5%, respectively. Multivariate analysis for LC showed that increased maximum tumour diameter (p = 0.011), type A dose calculation algorithm (p = 0.005), shorter overall treatment time of SBRT (p = 0.035) and colorectal primary origin (p p p = 0.013; 2–3 vs. 0, p p = 0.038), squamous cell carcinoma (vs. adenocarcinoma, p = 0.006) and increased maximum tumour diameter (p Conclusions Several factors of oligometastases and SBRT affected LC. LC of pulmonary oligometastases by SBRT showed a significant survival benefit compared to patients with local failure.
Databáze: OpenAIRE